Akriti G Jain

Dr. Akriti G Jain

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2022 in Annals of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
AJAkriti G Jain
Akriti G Jain
LZLing Zhang
Ling Zhang
JBJohn M. Bennett
John M. Bennett
RKRami Komrokji
Rami Komrokji
Akriti G. Jain, M.D., Ling Zhang, M.D., John M. Bennett, M.D., and Rami Komrokji, M.D.. Ann Lab Med 2022;42:299-305. https://doi.org/10.3343/alm.2022.42.3.299


1 February 2024 in Haematologica
Verified
Journal Article
Open access
PDF file
AJAkriti G Jain
Akriti G Jain
SBSomedeb Ball
Somedeb Ball
LALuis Aguirre
Luis Aguirre
NANajla Al Ali
Najla Al Ali
DKDavid Kaldas
David Kaldas
RKRami Komrokji
Rami Komrokji
The patterns of low-risk myelodysplastic syndrome (MDS) progression and the clinical and molecular features of those patterns have not been well described. We divided our low-risk (LR) MDS patients (N=1,914) into 4 cohorts: 1) patients who remained LR-MDS (LR-LR; N=1,300; 68%), 2) patients who progressed from LR to high-risk (HR) MDS (LR-HR) without transformation into acute myeloid leukemia (AML) (N=317; 16.5%), 3) patients who progressed from LR to HR MDS and then AML (LR-HR-AML; N=124; 6.5%), and 4) patients who progressed from LR MDS directly to AML (LR-AML; N=173; 9%). Risk factors for progression included: male gender, low absolute neutrophil count (ANC), low platelet count, high bone marrow (BM) blasts, ferritin >1000 mcg/L, albumin <3.5 g/dL, multi-lineage dysplasia (MLD), and lack of ring sideroblasts. Among patients with marked BM fibrosis (N=49), 18% progressed directly to AML. Somatic mutations (SM) associated with an increased risk of direct or indirect AML progression included SRSF2 and NRAS. SM in IDH1, IDH2 and NPM1 were more common in patients with direct AML transformation. SM associated with progression to higher risk disease only, without AML transformation, were ASXL1, TP53, RUNX1, and CBL. SF3B1 mutation was associated with less progression. About 171 patients (13.1% of all LR-LR patients) died within two years of diagnosis of LR-MDS without disease progression. Among the 61 cases with documented cause of death, 18 patients (29.5%) died from cytopenia and MDS-related complications. Identifying patterns of disease progression of LR MDS patients and their predictive factors will be crucial to be able to tailor therapy accordingly.

5 June 2022 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
DLDasom Lee
Dasom Lee
AJAkriti G Jain
Akriti G Jain
YDYehuda Deutsch
Yehuda Deutsch
JEJennifer Eatrides
Jennifer Eatrides
OCOnyee Chan
Onyee Chan
KSKendra Sweet
Kendra Sweet

18 April 2024 in Annals of Hematology
Verified
Journal Article
Open access
PDF file
AJAkriti G Jain
Akriti G Jain
QGQuinto Gesiotto
Quinto Gesiotto
SBSomedeb Ball
Somedeb Ball
LNLisa Nodzon
Lisa Nodzon
ARAmanda Rodriguez
Amanda Rodriguez
KSKendra Sweet
Kendra Sweet
Dasatinib is one of the second generation tyrosine kinase inhibitors (TKI) which is approved for the treatment of patients with chronic phase CML (CP-CML) both in the front line and in the second line setting. Pleural effusion (PE) is a unique toxicity associated with dasatinib use. Our aim was to study the incidence of pleural effusion in our cohort of patients who were treated with dasatinib for CP-CML and the safety upon TKI switch. A total of 390 patients were treated with dasatinib during their course of treatment for CP-CML. A total of 69 patients (17.6%) developed any grade of PE. About 33 (48%) patients developed CTCAE grade 2 PE, 34 (49%) grade 3 and only 1 patient developed grade 4 PE. Recurrence of PE was observed in 34 (49%) patients. While only 12 patients (17.3%) continued using dasatinib after development of PE, dasatinib was discontinued in the other 57 patients. Therapy was switched to bosutinib in 13 patients out of which 6 (46%) patients re-developed PE. While only 12.5% patients developed re-accumulation of pleural fluid in patients switched to imatinib, none of the patients switched to nilotinib re-developed PE. A change in TKI to bosutinib was associated with a 46% risk of recurrence of PE in patients who develop PE on dasatinib for the treatment of CP-CML. The incidence of recurrent PE was markedly lower in patient switched to imatinib or nilotinib.

11 March 2024 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
LALuis E. Aguirre
Luis E. Aguirre
AJAkriti G Jain
Akriti G Jain
SBSomedeb Ball
Somedeb Ball
NANajla Al Ali
Najla Al Ali
VVVirginia O. Volpe
Virginia O. Volpe
RKRami Komrokji
Rami Komrokji